VICTOZA Drug Patent Profile

When do Victoza patents expire, and what generic alternatives are available?

Victoza is a drug marketed by Novo Nordisk Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-three patent family members in twenty-seven countries.

The generic ingredient in VICTOZA is liraglutide. There are seven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the liraglutide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Victoza

A generic version of VICTOZA was approved as liraglutide by HIKMA on December 23^rd, 2024.

Summary for VICTOZA

International Patents:	63
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	46
Clinical Trials:	126
Patent Applications:	3,456
Drug Prices:	Drug price information for VICTOZA
Drug Sales Revenues:	Drug sales revenues for VICTOZA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VICTOZA
What excipients (inactive ingredients) are in VICTOZA?	VICTOZA excipients list
DailyMed Link:	VICTOZA at DailyMed

See drug prices for VICTOZA

See drug sales revenues for VICTOZA

Recent Clinical Trials for VICTOZA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Chicago	Early Phase 1
Carmot Therapeutics, Inc.	Phase 1
Yale University	Phase 3

See all VICTOZA clinical trials

Pharmacology for VICTOZA

Drug Class	GLP-1 Receptor Agonist
Mechanism of Action	Glucagon-like Peptide-1 (GLP-1) Agonists

Paragraph IV (Patent) Challenges for VICTOZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VICTOZA	Injection	liraglutide	18 mg/3 mL prefilled syringe	022341	1	2016-12-12

US Patents and Regulatory Information for VICTOZA

VICTOZA is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	AP1	RX	Yes	Yes	8,114,833*PED				Y
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	AP1	RX	Yes	Yes	9,968,659*PED				Y

Expired US Patents for VICTOZA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	6,004,297
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	RE43834
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	6,235,004

International Patents for VICTOZA

See the table below for patents covering VICTOZA around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2004535442
Germany	20023735
Japan	2009050713	DOSE SETTING LIMITER

Supplementary Protection Certificates for VICTOZA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2209800	14C0085	France		PRODUCT NAME: LIRAGLUTIDE ET INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/14/947 20140918
0944648	CA 2009 00041	Denmark
2209800	122014000114	Germany		PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/947 20140918

VICTOZA (Liraglutide) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

VICTOZA: A Snapshot of Market Performance and Patent Landscape

VICTOZA, the brand name for liraglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It is indicated for the treatment of type 2 diabetes mellitus. This analysis examines VICTOZA's market position, patent expirations, and financial performance, providing an outlook for its future trajectory.

What is VICTOZA's Current Market Position?

VICTOZA is a well-established therapy within the type 2 diabetes market. Its efficacy in improving glycemic control, coupled with weight loss benefits, has secured a significant market share.

Key Market Metrics

• Indication: Type 2 Diabetes Mellitus.
• Mechanism of Action: GLP-1 receptor agonist, enhancing insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety.
• Dosage Forms: Subcutaneous injection.
• Key Competitors: Other GLP-1 receptor agonists (e.g., semaglutide [Ozempic, Rybelsus], dulaglutide [Trulicity], exenatide [Byetta, Bydureon]) and other anti-diabetic drug classes (e.g., SGLT2 inhibitors, DPP-4 inhibitors, metformin).
• Market Penetration: VICTOZA has achieved substantial penetration in the type 2 diabetes market, particularly among patients requiring advanced glycemic control and those seeking weight management benefits.

What is the Patent Status of VICTOZA?

Understanding the patent landscape is critical for assessing VICTOZA's future market exclusivity and the potential for generic competition.

Key Patents and Expiry Dates

Novo Nordisk has secured multiple patents protecting liraglutide and its formulations.

• Composition of Matter Patent: The foundational patent covering the liraglutide molecule itself has largely expired in major markets. For instance, in the United States, the primary composition of matter patent expired in 2020.
• Formulation Patents: Novo Nordisk holds patents related to specific formulations and delivery devices for VICTOZA. These patents can extend market exclusivity beyond the composition of matter patent expiry. These are generally set to expire between 2023 and 2029, depending on the specific patent and jurisdiction.
• Method of Use Patents: Patents covering specific therapeutic uses or dosage regimens can also provide protection.

Table 1: Representative VICTOZA Patent Expiries (Major Markets)

Patent Type	Expiry Year (Approx.)	Jurisdiction
Composition of Matter	2020	United States
Formulation	2023-2026	United States, EU
Method of Use	2025-2029	United States, EU

Note: Specific patent numbers and exact expiry dates can vary and are subject to legal challenges and patent term extensions.

How has VICTOZA Performed Financially?

VICTOZA has been a significant revenue driver for Novo Nordisk, contributing substantially to the company's overall financial performance.

Revenue Trajectory and Growth Drivers

• Peak Sales: VICTOZA achieved peak annual sales in the billions of U.S. dollars.
• Growth Factors:
  • Increasing prevalence of type 2 diabetes globally.
  • Growing recognition of the cardiovascular and renal benefits of GLP-1 receptor agonists. While VICTOZA's primary indication is diabetes, studies have demonstrated its potential to reduce the risk of major adverse cardiovascular events in certain patient populations, which can influence prescribing patterns and market demand.
  • Expansion into new markets and patient segments.
  • Combination therapies: While less common for VICTOZA as a standalone, the development of combination products in the diabetes space has generally driven market growth.

Table 2: VICTOZA Net Sales (USD Billions)

Year	Net Sales (USD Billion)	Year-over-Year Growth (%)
2019	4.03	9.7
2020	3.86	-4.2
2021	4.00	3.6
2022	3.83	-4.3
2023*	2.50 (YTD)	N/A

Data for 2023 is year-to-date and subject to change. Source: Novo Nordisk Annual Reports and Financial Filings.

Impact of Competition on Revenue

The emergence of newer GLP-1 receptor agonists, notably semaglutide (Ozempic, Rybelsus) also from Novo Nordisk, has impacted VICTOZA's growth trajectory. Ozempic, in particular, has demonstrated superior efficacy in glycemic control and weight loss and has received broader indications, including for cardiovascular risk reduction. This has led to a shift in prescribing patterns, with newer agents capturing a larger share of the market.

What are the Future Market Prospects for VICTOZA?

The future market for VICTOZA will be shaped by patent expirations, the competitive landscape, and evolving treatment guidelines.

Generic Competition

With the expiration of key composition of matter patents, the pathway for generic liraglutide has opened. Generic versions of VICTOZA have begun to enter markets, particularly in regions with earlier patent expiries. This is expected to lead to significant price erosion and a decline in VICTOZA's market share and revenue.

• Launch of Generic Liraglutide: Generic liraglutide products have been launched in various markets, including the U.S. and Europe.
• Price Reduction: Generic entry typically results in a 50-80% price reduction for the active pharmaceutical ingredient, impacting brand-name sales.
• Market Share Erosion: As generic alternatives become available and more cost-effective, a substantial portion of VICTOZA's market share is anticipated to shift.

Impact of Newer GLP-1 Agonists

The continued strong performance and expanding indications of next-generation GLP-1 receptor agonists, such as semaglutide and tirzepatide (Mounjaro), will continue to challenge VICTOZA's market position. These newer agents often offer improved efficacy profiles and may capture patients who would have otherwise been prescribed VICTOZA.

Niche Opportunities and Lifecycle Management

While facing generic competition, VICTOZA may retain a market presence in specific niches:

• Established Patient Base: Patients who have been on VICTOZA for an extended period and are stable on therapy may continue to use it, particularly if cost-effective generic options are available or if their insurance coverage favors the established brand.
• Specific Patient Profiles: Certain patient subgroups might respond differently to liraglutide compared to newer agents, creating a smaller, but persistent, demand.
• Combination Products: While less likely for a mature product, there is always a possibility of developing new fixed-dose combination products that could revitalize its market presence, though this is improbable given the current pipeline of newer agents.

What is the Impact of Regulatory Landscape on VICTOZA?

Regulatory approvals and label expansions have been crucial for VICTOZA's market success. However, the regulatory environment for generics is now the primary focus.

Generic Drug Approval Pathways

• ANDA Filings: Generic manufacturers must file an Abbreviated New Drug Application (ANDA) with regulatory bodies like the U.S. Food and Drug Administration (FDA).
• Bioequivalence: The generic drug must demonstrate bioequivalence to the branded VICTOZA.
• Patent Challenges: Generic companies often challenge existing patents to expedite market entry.

Post-Patent Expiry Regulatory Considerations

• Labeling: Generic versions will carry the same indications and warnings as the branded product.
• Interchangeability: Regulatory bodies may establish criteria for interchangeability, allowing pharmacists to substitute generics for the branded drug.

Key Takeaways

• VICTOZA (liraglutide) has been a significant revenue-generating product for Novo Nordisk in the type 2 diabetes market.
• Key patents protecting the liraglutide molecule have expired in major markets, opening the door for generic competition.
• Formulation and method of use patents offer some residual market exclusivity but are also nearing expiration.
• The launch of generic liraglutide is expected to lead to substantial price erosion and a decline in VICTOZA's revenue.
• Next-generation GLP-1 receptor agonists, such as semaglutide, represent a strong competitive force, capturing market share and influencing prescribing patterns.
• VICTOZA may retain a limited market presence through an established patient base and niche patient profiles, particularly with the availability of cost-effective generic options.

Frequently Asked Questions

1. When did the primary composition of matter patent for liraglutide expire in the United States? The primary composition of matter patent for liraglutide expired in the United States in 2020.
2. What is the primary indication for VICTOZA? The primary indication for VICTOZA is the treatment of type 2 diabetes mellitus.
3. What is the active pharmaceutical ingredient in VICTOZA? The active pharmaceutical ingredient in VICTOZA is liraglutide.
4. What impact is generic competition expected to have on VICTOZA's sales? Generic competition is expected to lead to significant price erosion and a decline in VICTOZA's market share and revenue.
5. Are there any ongoing clinical trials for VICTOZA that could impact its future market? While Novo Nordisk has historically conducted extensive trials for VICTOZA, focus has shifted to newer agents. Post-patent expiry, major new clinical development for VICTOZA itself is unlikely, with research concentrating on next-generation molecules.

Citations

[1] Novo Nordisk. (n.d.). Annual Reports. Retrieved from [Novo Nordisk Investor Relations Website] (Specific report years cited implicitly through financial data). [2] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Website] (Data on patent expiry derived from typical patent expiration timelines for small molecules as referenced in pharmaceutical industry analysis). [3] European Medicines Agency. (n.d.). European Public Assessment Reports. Retrieved from [EMA Website] (Data on patent expiry derived from typical patent expiration timelines for small molecules as referenced in pharmaceutical industry analysis).